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ABSTRACT
We performed exome-wide association studies to identify single nucleotide 
polymorphisms that either influence fasting plasma glucose level or blood hemoglobin 
A1c content or confer susceptibility to type 2 diabetes mellitus in Japanese. Exome-
wide association studies were performed with the use of Illumina Human Exome-12 
DNA Analysis or Infinium Exome-24 BeadChip arrays and with 11,729 or 8635 subjects 
for fasting plasma glucose level or blood hemoglobin A1c content, respectively, or 
with 14,023 subjects for type 2 diabetes mellitus (3573 cases, 10,450 controls). 
The relation of genotypes of 41,265 polymorphisms to fasting plasma glucose level 
or blood hemoglobin A1c content was examined by linear regression analysis. After 
Bonferroni’s correction, 41 and 17 polymorphisms were significantly (P < 1.21 × 
10−6) associated with fasting plasma glucose level or blood hemoglobin A1c content, 
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respectively, with two polymorphisms (rs139421991, rs189305583) being associated 
with both. Examination of the relation of allele frequencies to type 2 diabetes mellitus 
with Fisher’s exact test revealed that 87 polymorphisms were significantly (P < 1.21 
× 10−6) associated with type 2 diabetes mellitus. Subsequent multivariable logistic 
regression analysis with adjustment for age and sex showed that four polymorphisms 
(rs138313632, rs76974938, rs139012426, rs147317864) were significantly (P 
< 1.44 × 10−4) associated with type 2 diabetes mellitus, with rs138313632 and 
rs139012426 also being associated with fasting plasma glucose and rs76974938 
with blood hemoglobin A1c. Five polymorphisms—rs139421991 of CAT, rs189305583 
of PDCL2, rs138313632 of RUFY1, rs139012426 of LOC100505549, and rs76974938 
of C21orf59—may be novel determinants of type 2 diabetes mellitus.
INTRODUCTION
Type 2 diabetes mellitus (DM) is a major cause 
of nephropathy, retinopathy, and neuropathy as well as 
cardiovascular disease and stroke [1, 2]. The heritability 
of type 2 DM has been estimated to be 50% to 60% [3]. 
Genome-wide association studies (GWASs) and meta-
analyses thereof have identified >80 susceptibility loci for 
type 2 DM in individuals of European [4–9] or African 
[10] ancestry, in East Asians [11], or in multiple ethnic 
groups [12]. Genetic variants identified in these previous 
studies typically have a minor allele frequency (MAF) of 
≥5% and a small individual effect size. Given that these 
common variants explain only a fraction of the heritability 
of type 2 DM, low-frequency (0.5% ≤ MAF < 5%) or 
rare (MAF < 0.5%) variants with larger effect sizes are 
also thought to contribute to the genetic architecture 
of this condition [13]. Among Japanese, GWASs have 
identified KCNQ1 [14, 15], UBE2E2, C2CD4A-B [16], 
ANK1 [17], MIR129-LEP, GPSM1, and SLC16A13 [18] 
as susceptibility genes for type 2 DM, and a recent meta-
analysis identified an additional seven susceptibility loci 
[19]. Genetic variants, including low-frequency and rare 
variants, that influence fasting plasma glucose (FPG) 
levels and blood glycosylated hemoglobin (HbA1c) content 
or which contribute to predisposition to type 2 DM in 
Japanese remain to be identified definitively, however.
We have now performed exome-wide association 
studies (EWASs) with the use of exome array–based 
genotyping methods to identify single nucleotide 
polymorphisms (SNPs)—especially low-frequency or rare 
coding variants with moderate to large effect sizes—that 
influence FPG levels and blood HbA1c content or which 
confer susceptibility to type 2 DM in Japanese. We used 
Illumina arrays that provide coverage of functional SNPs 
in entire exons including low-frequency and rare variants.
RESULTS
Characteristics of subjects
The characteristics of subjects are shown in Table 1. 
Age, the frequency of men, body mass index, and the 
prevalence of hypertension, dyslipidemia, chronic kidney 
disease, and hyperuricemia as well as systolic and diastolic 
blood pressure, serum concentrations of triglycerides, 
creatinine, and uric acid, FPG level, and blood HbA1c 
content were greater, whereas estimated glomerular 
filtration rate and the serum concentration of high density 
lipoprotein (HDL)–cholesterol were lower, in subjects 
with type 2 DM than in controls.
EWAS for FPG concentration
We examined the relation of genotypes of 41,265 
SNPs that passed quality control to FPG levels in 11,729 
subjects by linear regression analysis. A Manhattan plot 
for the EWAS is shown in Supplementary Figure 1A. 
After Bonferroni’s correction, 41 SNPs were significantly 
[P < 1.21 × 10−6 (0.05/41,265)] associated with FPG 
concentration (Table 2).
EWAS for blood HbA1c content
We examined the relation of genotypes of 41,265 
SNPs to blood HbA1c content in 8635 subjects by linear 
regression analysis. A Manhattan plot for the EWAS is 
shown in Supplementary Figure 1B. After Bonferroni’s 
correction, 17 SNPs were significantly (P < 1.21 × 10–6) 
associated with blood HbA1c content (Table 3). SNPs 
rs139421991 [G/A (R320Q)] of CAT and rs189305583 
[C/T (V69I)] of PDCL2 were significantly associated with 
both FPG level and blood HbA1c content.
EWAS for type 2 DM
The EWAS for type 2 DM was performed with 
14,023 subjects (3573 individuals with type 2 DM, 10,450 
controls). We examined the relation of allele frequencies 
of 41,265 SNPs to type 2 DM with Fisher’s exact test. A 
Manhattan plot for the EWAS is shown in Supplementary 
Figure 1C. After Bonferroni’s correction, 87 SNPs were 
significantly (P < 1.21 × 10−6) associated with type 2 DM 
(Supplementary Table 1). The genotype distributions of 
these SNPs were in Hardy-Weinberg equilibrium (P > 
0.001) among controls (Supplementary Table 2).
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The relation of these 87 SNPs to type 2 DM was 
examined further by multivariable logistic regression 
analysis with adjustment for age and sex (Supplementary 
Table 3). Four SNPs—rs138313632 [T/G (S705A)] 
of RUFY1, rs76974938 [C/T (D67N)] of C21orf59, 
rs139012426 [G/C (S1242T)] of LOC100505549, and 
rs147317864 [C/T (A262T)] of TRABD2B—were 
significantly [P < 1.44 × 10−4 (0.05/348)] associated with 
type 2 DM (Table 4). The minor G, T, and C alleles of 
rs138313632, rs76974938, and rs139012426, respectively, 
were protective against type 2 DM, whereas the minor T 
allele of rs147317864 was a risk factor for this condition. 
SNPs rs138313632 of RUFY1 and rs139012426 of 
LOC100505549 were significantly associated with 
both FPG level and type 2 DM, whereas rs76974938 of 
C21orf59 was significantly associated with both blood 
HbA1c content and type 2 DM.
Relation of SNPs to FPG level or blood HbA1c 
content
We examined the relation of genotypes of identified 
SNPs to the FPG level or blood HbA1c content by one-way 
analysis of variance (ANOVA). The 41 SNPs identified 
in the EWAS for FPG level, including the two SNPs 
(rs138313632, rs139012426) also found to be associated 
with type 2 DM, were all significantly [P < 0.0012 (0.05/43)] 
associated with FPG level. The remaining two SNPs 
associated with type 2 DM (rs76974938, rs147317864) were 
not significantly related to the FPG level (Table 5).
Table 1: Characteristics of the 14,023 study subjects
Characteristic Type 2 DM Controls P
No. of subjects 3573 10,450
Age (years) 66.2 ± 11.5 59.5 ± 13.8 <0.0001
Sex (male/female, %) 66.8/33.2 52.7/47.3 <0.0001
Body mass index (kg/m2) 24.2 ± 3.8 23.0 ± 3.3 <0.0001
Current or former smoker (%) 38.5 35.8 0.0067
Hypertension (%) 76.9 45.6 <0.0001
Systolic blood pressure (mmHg) 141 ± 26 128 ± 22 <0.0001
Diastolic blood pressure (mmHg) 78 ± 15 76 ± 13 <0.0001
Dyslipidemia (%) 75.4 56.7 <0.0001
Serum triglycerides (mmol/L) 1.68 ± 1.25 1.38 ± 0.92 <0.0001
Serum HDL-cholesterol (mmol/L) 1.31 ± 0.41 1.57 ± 0.46 <0.0001
Serum LDL-cholesterol (mmol/L) 3.08 ± 0.97 3.13 ± 0.81 0.0159
Chronic kidney disease (%) 34.5 20.4 <0.0001
Serum creatinine (μmol/L) 94.9 ± 123.5 73.1 ± 64.4 <0.0001
Estimated GFR (mL min−1 1.73 m–2) 68.8 ± 24.1 73.4 ± 19.1 <0.0001
Hyperuricemia (%) 22.4 15.8 <0.0001
Serum uric acid (μmol/L) 336 ± 101 325 ± 92 <0.0001
Fasting plasma glucose (mmol/L) 8.81 ± 3.66 5.38 ± 0.77 <0.0001
Blood HbA1c (%) 7.15 ± 1.73 5.48 ± 0.39 <0.0001
Quantitative data are means ± SD and were compared between subjects with type 2 DM and controls with the unpaired 
Student’s t test. Categorical data were compared between the two groups with Fisher’s exact test. Based on Bonferroni’s 
correction, a P value of <0.0028 (0.05/18) was considered statistically significant. Hypertension: systolic blood pressure 
of ≥140 mmHg, diastolic blood pressure of ≥90 mmHg, or taking of anti-hypertensive medication. Dyslipidemia: serum 
triglyceride concentration of ≥1.65 mmol/L, serum high density lipoprotein (HDL)–cholesterol concentration of <1.04 
mmol/L, serum low density lipoprotein (LDL)–cholesterol concentration of ≥3.64 mmol/L, or taking of anti-dyslipidemic 
medication. Chronic kidney disease: estimated glomerular filtration rate (eGFR) of <60 mL min–1 1.73 m–2, where eGFR 
(mL min–1 1.73 m–2) = 194 × (age in years)–0.287 × (serum creatinine in mg/dL)–1.094 (× 0.739 if female). Hyperuricemia: 
serum concentration of uric acid of >416 μmol/L.
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Table 2: The 41 SNPs significantly (P < 1.21 × 10−6) associated with FPG level in the EWAS
Gene dbSNP Nucleotide (amino acid) substitutiona
Chromosome: 
position MAF (%) P (genotype)
OR4F6 rs141569282 G/A (A117T) 15: 101806068 1.7 1.07 × 10−12
SLC35F3 rs140011243 T/G (C144G) 1: 234231563 0.5 1.56 × 10−11
RUFY1 rs138313632 T/G (S705A) 5: 179609505 0.5 9.91 × 10−11
KARS rs201151665 A/T (M29L) 16: 75647967 0.4 3.98 × 10−10
IFITM5 rs146230729 G/T (P31T) 11: 299400 0.5 6.30 × 10−10
CADM1 rs561567580 G/C (R7P) 11: 115504375 0.4 6.76 × 10−10
PPP1R9B rs113281588 G/C (G311A) 17: 50149582 0.5 1.57 × 10−9
MUC17 rs78010183 A/T (T1305S) 7: 101035329 1.8 1.63 × 10−9
CCDC166 rs75368383 T/C (K187R) 8: 143707454 0.5 1.70 × 10−9
SCAMP4 rs150715312 A/G (K69E) 19: 1912252 0.6 1.74 × 10−9
PLEC rs201654895 A/G (M3874V) 8: 143918282 0.4 2.21 × 10−9
LGR5 rs117324318 G/A 12: 71440257 0.4 2.68 × 10−9
CCDC114 rs140189114 C/T (G632R) 19: 48297095 0.4 3.82 × 10−9
NLRC3 rs116433328 G/C (M286I) 16: 3564079 0.4 6.74 × 10−9
CECR2 rs201989565 G/A 22: 17548704 0.4 1.12 × 10−8
DUS2 rs202069030 G/C (R51S) 16: 68023050 0.4 1.14 × 10−8
SIGLEC1 rs201950990 A/C (V69G) 20: 3706550 0.5 2.11 × 10−8
ALKBH1 rs200168197 A/C (V329G) 14: 77673996 0.4 2.72 × 10−8
TNFRSF4 rs150516264 A/G (L98P) 1: 1213069 0.4 2.95 × 10−8
LOC100505549 rs139012426 G/C (S1242T) 18: 57648519 0.4 3.64 × 10−8
ADAD2 rs149894736 C/T (P107L) 16: 84191550 0.7 3.70 × 10−8
YBEY rs200145138 C/G (L148V) 21: 46297572 0.4 3.84 × 10−8
PRKCDBP rs11544766 C/G (T68S) 11: 6320274 0.4 5.38 × 10−8
MYLIP rs201021082 T/C (V17A) 6: 16129372 0.4 5.47 × 10−8
MGAT3 rs201417286 T/G (V200G) 22: 39487946 0.3 6.54 × 10−8
B3GNT6 rs559157215 A/G (H301R) 11: 77040453 0.3 7.38 × 10−8
KNDC1 rs146093427 A/G (N546D) 10: 133195723 0.4 8.57 × 10−8
TNXB rs141190850 T/C (D677G) 6: 32095823 0.3 8.62 × 10−8
PCDHAC1 rs185216314 A/G (Q479R) 5: 140968202 0.1 1.40 × 10−7
CSPG4 rs137981794 T/C (D1936G) 15: 75676712 0.4 1.50 × 10−7
DNAJB2 rs148615702 C/G (Q235E) 2: 219284715 0.3 1.63 × 10−7
FGD3 rs116496123 G/T 9: 93034624 0.7 1.71× 10−7
AK8 rs150636539 G/A (P328S) 9: 132792773 0.3 2.04 × 10−7
LAMB3 rs202068754 A/C (V753G) 1: 209623605 0.4 2.06 × 10−7
GDPD3 rs200801803 G/A 16: 30112132 0.3 2.95 × 10−7
CAT rs139421991 G/A (R320Q) 11: 34456720 0.3 3.01 × 10−7
OAS3 rs62623451 G/A (A49T) 12: 112938675 0.3 3.13 × 10−7
NOTCH1 rs201053795 T/C (T970A) 9: 136509794 0.6 3.43 × 10−7
PDCL2 rs189305583 C/T (V69I) 4: 55580834 0.1 4.24 × 10−7
SYNM rs200549249 G/A (G235E) 15: 99105903 0.2 7.54 × 10−7
SNTB1 rs145615160 A/G (Y57H) 8: 120811675 0.5 1.09 × 10−6
The relation of genotypes of SNPs to FPG level was examined by linear regression analysis. aMajor allele/minor allele.
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Table 3: The 17 SNPs significantly (P < 1.21 × 10−6) associated with blood HbA1c content in the EWAS
Gene dbSNP Nucleotide (amino acid) substitutiona
Chromosome: 
position MAF (%) P (genotype)
PTCHD3 rs77473776 T/G (Q186K) 10: 27413695 30.6 3.59 × 10−38
C21orf59 rs76974938 C/T (D67N) 21: 32609946 2.4 1.68 × 10−27
TNC rs138406927 C/T (A1096T) 9: 115064848 2.1 4.60 × 10−27
KRR1 rs17115182 G/A (P43S) 12: 75508405 7 5.17 × 10−22
ZNF43 rs149604219 G/A (A93V) 19: 21809741 3 7.87 × 10−17
PRCP rs2229437 T/G (E133D) 11: 82853252 6.4 9.82 × 10−12
CYP4F12 rs609636 G/A (D76N) 19: 15678288 2.3 4.74 × 10−11
rs1917321 A/C 11: 49356208 35.5 3.33 × 10−10
LGALS14 rs72480733 G/A (R27H) 19: 39705987 36.7 2.19 × 10−8
ANKRD26 rs12572862 C/G (L1219V) 10: 27033374 21.7 1.35 × 10−7
CAT rs139421991 G/A (R320Q) 11: 34456720 0.3 1.69 × 10−7
ZKSCAN3 rs13201752 A/G (K200E) 6: 28363350 36.5 2.60 × 10−7
rs10451497 C/T 19: 15093055 31.2 5.29 × 10−7
OR8H3 rs61751933 C/T (T16M) 11: 56122419 18.3 7.54 × 10−7
PDCL2 rs189305583 C/T (V69I) 4: 55580834 0.1 8.56 × 10−7
HIVEP1 rs200286173 A/G (Y374C) 6: 12120916 0.2 9.93 × 10−7
RSL24D1 rs200023487 A/G (V28A) 15: 55192832 0.1 1.20 × 10−6
The relation of genotypes of SNPs to blood HbA1c content was examined by linear regression analysis. aMajor allele/minor 
allele.
Table 4: Relation of SNPs to type 2 DM as determined by multivariable logistic regression analysis
Gene SNP
Dominant Recessive Additive 1 Additive 2
P OR  
(95% CI)
P OR  
(95% CI)
P OR  
(95% CI)
P OR  
(95% CI)
RUFY1 rs138313632 T/G (S705A) 4.20 × 10−8 0.20 (0.09–0.39) ND 4.20 × 10
−8 0.20 
(0.09–0.39) ND
C21orf59 rs76974938 C/T (D67N) 1.00 × 10−23 0.33 (0.26–0.41) ND 1.00 × 10
−23 0.33 
(0.26–0.41) ND
LOC100505549 rs139012426 G/C (S1242T) 2.28 × 10
−6 0.22 
(0.09–0.44) ND 2.28 × 10
−6 0.22 
(0.09–0.44) ND
TRABD2B rs147317864 C/T (A262T) 2.25 × 10−5 1.21 × 10
8 
(ND) ND 2.25 × 10
−5 1.21 × 10
8 
(ND) ND
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, 
P values of <1.44 × 10−4 (0.05/348) were considered statistically significant and are shown in bold. OR, odds ratio; CI, 
confidence interval; ND, not determined.
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Table 5: Relation of SNPs to FPG level
SNP FPG (mmol/L) P
Associated with FPG level and type 2 DM
rs138313632 T/G (S705A) TT TG
6.25 ± 2.45 4.92 ± 1.66 9.91 × 10−11
rs139012426 G/C (S1242T) GG GC
6.24 ± 2.44 4.96 ± 1.83 3.64 × 10−8
Associated with FPG level
rs141569282 G/A (A117T) GG GA
6.38 ± 2.65 5.50 ± 0.90 1.07 × 10−12
rs140011243 T/G (C144G) TT TG
6.24 ± 2.44 4.87 ± 1.63 1.56 × 10−11
rs201151665 A/T (M29L) AA AT
6.24 ± 2.44 4.81 ± 1.14 3.98 × 10−10
rs146230729 G/T (P31T) GG GT
6.24 ± 2.44 4.98 ± 1.72 6.30 × 10−10
rs561567580 G/C (R7P) GG GC
6.24 ± 2.44 4.96 ± 1.74 6.76 × 10−10
rs113281588 G/C (G311A) GG GC
6.22 ± 2.44 5.00 ± 1.73 1.57 × 10−9
rs78010183 A/T (T1305S) AA AT
6.25 ± 2.47 5.63 ± 1.39 1.63 × 10−9
rs75368383 T/C (K187R) TT TC
6.25 ± 2.44 5.02 ± 1.69 1.70 × 10−9
rs150715312 A/G (K69E) AA AG
6.25 ± 2.45 5.15 ± 1.70 1.74 × 10−9
rs201654895 A/G (M3874V) AA AG
6.24 ± 2.44 4.96 ± 1.19 2.21 × 10−9
rs117324318 G/A GG GA
6.24 ± 2.44 5.01 ± 1.73 2.68 × 10−9
rs140189114 C/T (G632R) CC CT
6.24 ± 2.44 4.96 ± 1.75 3.82 × 10−9
rs116433328 G/C (M286I) GG GC
6.24 ± 2.44 4.93 ± 1.77 6.74 × 10−9
rs201989565 G/A GG GA
6.24 ± 2.44 5.00 ± 1.76 1.12 × 10−8
rs202069030 G/C (R51S) GG GC
6.24 ± 2.44 4.91 ± 1.74 1.14 × 10−8
(Contined )
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SNP FPG (mmol/L) P
rs201950990 A/C (V69G) AA AC
6.24 ± 2.44 5.08 ± 1.79 2.11 × 10−8
rs200168197 A/C (V329G) AA AC
6.24 ± 2.44 4.97 ± 1.84 2.72 × 10−8
rs150516264 A/G (L98P) AA AG
6.24 ± 2.44 5.03 ± 1.81 2.95 × 10−8
rs149894736 C/T (P107L) CC CT
6.24 ± 2.44 5.25 ± 1.57 3.70 × 10−8
rs200145138 C/G (L148V) CC CG
6.24 ± 2.44 4.98 ± 1.92 3.84 × 10−8
rs11544766 C/G (T68S) CC CG
6.24 ± 2.44 5.01 ± 1.77 5.38 × 10−8
rs201021082 T/C (V17A) TT TC
6.24 ± 2.43 4.98 ± 1.89 5.47 × 10−8
rs201417286 T/G (V200G) TT TG
6.24 ± 2.44 4.98 ± 1.85 6.54 × 10−8
rs559157215 A/G (H301R) AA AG
6.24 ± 2.43 4.90 ± 1.87 7.38 × 10−8
rs146093427 A/G (N546D) AA AG
6.24 ± 2.44 5.09 ± 1.80 8.57 × 10−8
rs141190850 T/C (D677G) TT TC
6.24 ± 2.43 4.91 ± 1.92 8.62 × 10−8
rs185216314 A/G (Q479R) AA AG
6.21 ± 2.41 8.38 ± 6.21 1.40 × 10−7
rs137981794 T/C (D1936G) TT TC
6.24 ± 2.44 5.06 ± 1.88 1.50 × 10−7
rs148615702 C/G (Q235E) CC CG
6.24 ± 2.44 4.86 ± 2.00 1.63 × 10−7
rs116496123 G/T GG GT
6.24 ± 2.46 5.36 ± 1.87 1.71 × 10−7
rs150636539 G/A (P328S) GG GA
6.24 ± 2.44 4.93 ± 1.88 2.04 × 10−7
rs202068754 A/C (V753G) AA AC
6.24 ± 2.44 5.10 ± 1.86 2.06 × 10−7
rs200801803 G/A GG GA
6.24 ± 2.44 4.88 ± 1.98 2.95 × 10−7
rs139421991 G/A (R320Q) GG GA
6.17 ± 2.35 7.43 ± 3.08 3.01 × 10−7
(Contined )
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The 17 SNPs identified in the EWAS for blood 
HbA1c content, including the one SNP (rs76974938) 
also found to be associated with type 2 DM, were all 
significantly [P < 0.0025 (0.05/20)] associated with 
blood HbA1c content by one-way ANOVA. The remaining 
three SNPs associated with type 2 DM (rs138313632, 
rs139012426, rs147317864) were not significantly related 
to blood HbA1c content (Table 6).
Relation of identified SNPs to phenotypes 
examined in previous GWASs
We examined the genes, chromosomal loci, and 
SNPs identified in the present study to DM-related 
phenotypes examined in previous GWASs deposited in a 
public database [GWAS Catalog (http://www.ebi.ac.uk/
gwas)]. LGR5 has been previously shown to be related to 
type 2 DM, whereas TNXB has been previously associated 
with type 1 DM and PTCHD3 with fasting insulin-related 
traits (Supplementary Table 4). The remaining 54 SNPs 
identified in the present study have not been previously 
found to be related to DM-related phenotypes.
Network analysis of the genes identified in the 
present study
We performed network analysis of the top ten (high 
scores) genes that have been shown to be associated with 
type 2 DM selected from DisGeNET database (http://
www.disgenet.org/web/DisGeNET) and four genes (CAT, 
PDCL2, RUFY1, and C21orf59) identified in the present 
study by the use of Cytoscape version 3.4.0 software 
(http://www.cytoscape.org/). Given that LOC100505549 
protein has not been characterized, it could not be 
examined. The network analysis showed that CAT, 
PDCL2, RUFY1, and C21orf59 have potential indirect 
interactions with several genes previously shown to be 
associated with type 2 DM (Supplementary Figure 2).
DISCUSSION
We have now shown that two SNPs—rs139421991 
[G/A (R320Q)] of CAT and rs189305583 [C/T (V69I)] 
of PDCL2—were significantly associated with both 
FPG levels and blood HbA1c content; two SNPs—
rs138313632 [T/G (S705A)] of RUFY1 and rs139012426 
[G/C (S1242T)] of LOC100505549—were significantly 
associated with both FPG levels and type 2 DM; and 
one SNP, rs76974938 [C/T (D67N)] of C21orf59, was 
significantly associated with both blood HbA1c content 
and type 2 DM. These five SNPs may thus be novel 
determinants of type 2 DM. Given that FPG levels are 
affected by meals of the day before examination, we 
selected the SNPs and genes that were associated with 
both FPG levels and blood HbA1c or type 2 DM.
The catalase gene (CAT) is located at chromosomal 
region 11p13 (NCBI Gene, https://www.ncbi.nlm.nih.
gov/gene) and is expressed in various tissues and organs 
SNP FPG (mmol/L) P
rs62623451 G/A (A49T) GG GA
6.24 ± 2.44 5.03 ± 1.85 3.13 × 10−7
rs201053795 T/C (T970A) TT TC
6.24 ± 2.45 5.27 ± 1.87 3.43 × 10−7
rs189305583 C/T (V69I) CC CT
6.21 ± 2.41 8.26 ± 5.49 4.24 × 10−7
rs200549249 G/A (G235E) GG GA
6.23 ± 2.44 4.76 ± 1.12 7.54 × 10−7
rs145615160 A/G (Y57H) AA AG
6.24 ± 2.44 5.26 ± 2.15 1.09 × 10−6
Associated with type 2 DM
rs76974938 C/T (D67N) CC CT
6.21 ± 2.46 6.46 ± 2.27 0.0758
rs147317864 C/T (A262T) CC
6.21 ± 2.46 ND
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0012 
(0.05/43) were considered statistically significant and are shown in bold. ND, not determined.
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Table 6: Relation of SNPs to blood HbA1c content
SNP Blood HbA1c (%) P
Associated with blood HbA1c content and type 2 DM
rs76974938 C/T (D67N) CC CT
6.04 ± 1.25 5.47 ± 0.68 <1.0 × 10−23
Associated with blood HbA1c content
rs77473776 T/G (Q186K) TT TG GG
6.03 ± 1.28 5.85 ± 1.12 5.47 ± 0.63 <1.0 × 10−23
rs138406927 C/T (A1096T) CC CT
6.04 ± 1.25 5.44 ± 0.61 <1.0 × 10−23
rs17115182 G/A (P43S) GG GA
6.04 ± 1.25 5.48 ± 0.57 5.20 × 10−22
rs149604219 G/A (A93V) GG GA
5.95 ± 1.21 5.44 ± 0.51 7.87 × 10−17
rs2229437 T/G (E133D) TT TG GG
5.89 ± 1.14 6.15 ± 1.44 6.26 ± 1.32 6.94 × 10−11
rs609636 G/A (D76N) GG GA
6.01 ± 1.24 5.31 ± 0.50 4.74 × 10−11
rs1917321 A/C AA AC CC
5.87 ± 1.09 6.02 ± 1.26 6.10 ± 1.37 1.11 × 10−9
rs72480733 G/A (R27H) GG GA AA
5.85 ± 1.10 5.94 ± 1.23 6.09 ± 1.30 9.51 × 10−8
rs12572862 C/G (L1219V) CC CG GG
5.92 ± 1.21 6.06 ± 1.33 6.18 ± 1.34 8.99 × 10−7
rs139421991 G/A (R320Q) GG GA
5.89 ± 1.14 6.64 ± 1.50 1.69 × 10−7
rs13201752 A/G (K200E) AA AG GG
6.05 ± 1.24 5.90 ± 1.20 5.87 ± 1.09 3.47 × 10−7
rs10451497 C/T CC CT TT
6.02 ± 1.21 5.93 ± 1.27 5.78 ± 0.92 2.03 × 10−6
rs61751933 C/T (T16M) CC CT TT
6.04 ± 1.26 5.88 ± 1.16 5.91 ± 1.04 8.58 × 10−7
rs189305583 C/T (V69I) CC CT
5.90 ± 1.17 7.00 ± 2.87 8.56 × 10−7
rs200286173 A/G (Y374C) AA AG
5.90 ± 1.17 6.99 ± 2.46 9.93 × 10−7
rs200023487 A/G (V28A) AA AG
5.90 ± 1.17 7.04 ± 2.55 1.20 × 10−6
(Contined )
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including the pancreas (The Human Protein Atlas, http://
www.proteinatlas.org). Catalase catalyzes the breakdown 
of hydrogen peroxide into oxygen and water. Inherited 
catalase deficiency has been associated with an increased 
prevalence of type 2 DM in Hungarians [20–22]. The 
frequency of various CAT mutations has been found to be 
increased in individuals with DM, especially in females 
with type 2 DM, and such inherited catalase deficiency is 
associated with an early onset of type 2 DM [20]. We have 
now shown that rs139421991 [G/A (R320Q)] of CAT was 
significantly associated with both FPG levels and blood 
HbA1c content, with the minor A allele being related to 
an increase in these parameters. This association of CAT 
with type 2 DM may be attributable to the role of the 
encoded protein in the metabolism of hydrogen peroxide 
and oxidative stress, although the underlying molecular 
mechanism remains to be determined.
The phosducin like 2 gene (PDCL2) is located at 
chromosome 4q12 (NCBI Gene) and is expressed at a high 
level in testis (The Human Protein Atlas). The PDCL2 
protein belongs to the phosducin family [23]. PDCL1 has 
been shown to be essential for G protein signaling as a 
result of its role in folding and assembly of the Gβγ dimer. 
PDCL2 and PDCL3 likely assist in the folding of actin, 
tubulin, and proteins that activate cell cycle progression 
[24]. We have now shown that rs189305583 [C/T (V69I)] 
of PDCL2 was significantly associated with both the FPG 
concentration and blood HbA1c content, with the minor 
T allele being related to increases in these parameters. 
Given that G protein–coupled receptor signaling promotes 
insulin secretion and the proliferation of pancreatic β cells 
[25], the association PDCL2 with FPG levels and blood 
HbA1c content may be attributable to an effect of PDCL2 
on such signaling, although the molecular mechanism 
remains unclear.
The RUN and FYVE domain containing 1 gene 
(RUFY1) is located at chromosomal region 5q35.3 (NCBI 
Gene) and is expressed in various tissues and organs 
including the pancreas (The Human Protein Atlas). The 
RUFY1 protein binds to phosphatidylinositol 3-phosphate 
and promotes early endosomal trafficking including the 
tethering and fusion of vesicles through interactions with 
small GTPases such as Rab4, Rab5, and Rab14 [26]. 
We have now shown that rs138313632 [T/G (S705A)] 
of RUFY1 was significantly associated with both FPG 
concentration and type 2 DM, with the minor G allele 
being related to a decreased FPG level and a reduced risk 
for type 2 DM. Given that small GTPases enhances insulin 
granule exocytosis [27], the association of RUFY1 with 
both FPG levels and type 2 DM may be attributable to an 
effect of the encoded protein on insulin secretion.
The uncharacterized LOC100505549 gene is located 
at chromosome 18q21.31 (NCBI Gene). The function of 
LOC100505549 remains unknown. We have now shown 
that rs139012426 [G/C (S1242T)] of LOC100505549 
was significantly associated with both FPG levels and 
type 2 DM, with the minor C allele being related to a 
decreased FPG concentration and a reduced risk of type 2 
DM, although the functional relevance of this association 
remains unknown.
The chromosome 21 open reading frame 59 gene 
(C21orf59) is located at chromosome 21q22.11 (NCBI 
Gene) and is expressed in various tissues and organs 
including the pancreas (The Human Protein Atlas). The 
C21orf59 protein promotes dynein arm assembly in motile 
cilia, and mutations in C21orf59 cause ciliary dyskinesia 
[28]. Ciliopathies are associated with pancreatic defects 
that manifest mostly as cysts originating from ductal cells. 
Ciliary proteins have been suggested to influence insulin 
secretion and energy regulation [29, 30]. We have now 
shown that rs76974938 [C/T (D67N)] of C21orf59 was 
significantly associated with both blood HbA1c content 
and type 2 DM, with the minor T allele being related to 
a decreased blood HbA1c content and a reduced risk for 
type 2 DM. Given that C21orf59 may activate ciliary 
function and that cilia influence insulin secretion [29, 30], 
the association of C21orf59 with blood HbA1c content and 
type 2 DM might reflect an effect of this gene on insulin 
SNP Blood HbA1c (%) P
Associated with type 2 DM
rs138313632 T/G (S705A) TT
5.90 ± 1.18 ND
rs139012426 G/C (S1242T) GG GC
5.90 ± 1.18 8.2 0.0504
rs147317864 C/T (A262T) CC
6.02 ± 1.24 ND
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0025 
(0.05/20) were considered statistically significant and are shown in bold. ND, not determined.
Oncotarget80502www.impactjournals.com/oncotarget
secretion, although the underlying molecular mechanism 
remains unclear.
In previous GWASs of type 2 DM in the Japanese 
population [14–19], the MAF of identified SNPs ranged 
from 2% to 48% and the odds ratio (OR) from 0.38 to 
1.70. In a meta-analysis of GWASs for type 2 DM in 
East Asian populations [11] and in a trans-ancestry meta-
analysis of GWASs for type 2 DM [12], the OR ranged 
from 1.06 to 1.10 or from 1.08 to 1.13, respectively. In 
our study, we identified four SNPs associated with type 
2 DM, with the MAF and OR in a dominant model of 
logistic regression analysis for rs138313632, rs76974938, 
rs139012426, and rs147317864 being 0.5% and 0.20, 
2.4% and 0.33, 0.4% and 0.22, and 0.2% and 1.21 × 108, 
respectively. Both rs138313632 and rs76974938 were 
thus low-frequency variants with a moderate effect size, 
whereas rs139012426 and rs147317864 were rare variants 
with a moderate to large effect size.
Two SNPs (MAF and differences in FPG level or 
blood HbA1c content between genotypes, respectively, 
shown in parentheses) associated with both FPG 
concentration and blood HbA1c content—rs139421991 of 
CAT (0.3%, 17.0%, 11.3%) and rs189305583 of PDCL2 
(0.1%, 24.8%, 15.7%)—were rare variants with a large 
effect size; two SNPs associated with both FPG levels 
and type 2 DM—rs138313632 of RUFY1 (0.5%, 21.3%, 
22.4%) and rs139012426 of LOC100505549 (0.4%, 
20.5%, 28.0%)—were rare or low-frequency variants with 
a large effect size; and one SNP associated with both blood 
HbA1c content and type 2 DM, rs76974938 of C21orf59 
(2.4%, 4.3%, 9.4%), was a low-frequency variant with 
a moderate effect size. Among the remaining 37 SNPs 
associated with FPG levels, 25 SNPs were rare variants 
with a large effect size and 12 SNPs were low-frequency 
variants with a moderate to large effect size. Among the 
remaining 14 SNPs associated with blood HbA1c content, 
two SNPs were rare variants with a large effect size, three 
SNPs were low-frequency variants with a moderate to 
large effect size, and nine SNPs were common variants 
with a small to moderate effect size (Supplementary 
Table 5).
There are several limitations to the present study. 
(i) Given that our results were not replicated, they will 
require validation in other subject panels or in other 
ethnic groups. (ii) There is a possibility that some control 
individuals are prediabetic. (iii) It is possible that SNPs 
identified in the present study are in linkage disequilibrium 
with other polymorphisms in other nearby genes that 
are actually determinants of FPG levels, blood HbA1c 
content, or the development of type 2 DM. (iv) One SNP 
associated with type 2 DM was not significantly related 
to FPG level or blood HbA1c content, a discrepancy that 
may be attributable to the effects of medical treatment. (v) 
The biological or functional evidence of the association of 
the identified SNPs with FPG level, blood HbA1c content, 
or type 2 DM remains to be determined. Because of lack 
of experiments for functional analyses, the association of 
the SNPs identified in the present study with type 2 DM, 
FPG levels, or blood HbA1c content should be interpreted 
carefully.
In conclusion, we have identified five SNPs—
rs139421991 [G/A (R320Q)] of CAT, rs189305583 
[C/T (V69I)] of PDCL2, rs138313632 [T/G (S705A)] of 
RUFY1, rs139012426 [G/C (S1242T)] of LOC100505549, 
and rs76974938 [C/T (D67N)] of C21orf59—as novel 
determinants of type 2 DM. We also identified 37, 14, 
or one SNPs as candidate determinants of FPG levels, 
blood HbA1c content, and type 2 DM, respectively. 
Determination of genotypes for these SNPs may prove 
informative for assessment of the genetic risk for type 2 
DM in Japanese.
MATERIALS AND METHODS
Study subjects
A total of 14,023 individuals was examined. The 
subjects were recruited as described previously [31].
Type 2 DM was defined according to the criteria of 
the World Health Organization as described previously 
[32–34]. Subjects with type 2 DM had an FPG level of 
≥6.93 mmol/L (126 mg/dL) or a blood HbA1c content of 
≥6.5% or were taking antidiabetes medication. We thus 
examined 3573 subjects with type 2 DM and 10,450 
controls. Individuals with type 1 DM, maturity-onset 
diabetes of the young, DM associated with mitochondrial 
diseases or single-gene disorders, pancreatic diseases, or 
other metabolic or endocrinologic diseases were excluded 
from the study. Those taking medications that may cause 
secondary DM were also excluded. The control subjects 
had an FPG level of <6.05 mmol/L (110 mg/dL), a blood 
HbA1c content of <6.2%, and no history of DM or of 
having taken antidiabetes medication. Autopsy cases were 
excluded from controls.
The study protocol complied with the Declaration 
of Helsinki and was approved by the Committees on the 
Ethics of Human Research of Mie University Graduate 
School of Medicine, Hirosaki University Graduate School 
of Medicine, Tokyo Metropolitan Institute of Gerontology, 
and participating hospitals. Written informed consent was 
obtained from all subjects or families of the deceased 
subjects.
EWASs
Methods for sample collection and extraction 
of genomic DNA have been described previously 
[31]. EWASs for FPG concentration and blood HbA1c 
content included 11,729 and 8635 subjects, respectively, 
whereas that for type 2 DM included 14,023 individuals 
(3573 subjects with type 2 DM, 10,450 controls). Data 
for FPG levels were obtained from subjects who had 
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fasted overnight. Data for blood HbA1c content were 
obtained from subjects with type 2 DM or impaired 
glucose tolerance or from those who had annual health 
checkup. The EWASs were performed with the use of a 
HumanExome-12 v1.1 or v1.2 DNA Analysis BeadChip or 
Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, 
CA, USA). Detailed information of the exome arrays and 
methods of quality control have been described previously 
[31]. Genotype data were examined for population 
stratification by principal components analysis [35] 
(Supplementary Figure 3). A total of 41,265 SNPs passed 
quality control and was subjected to analysis.
Statistical analysis
The relation of genotypes of SNPs to FPG level 
or blood HbA1c content in the EWASs was examined by 
linear regression analysis. For analysis of characteristics 
of the study subjects, quantitative and categorical data 
were compared between individuals with type 2 DM and 
controls with the unpaired Student’s t test or Fisher’s exact 
test, respectively. Allele frequencies were estimated by the 
gene counting method, and Fisher’s exact test was used 
to identify departure from Hardy-Weinberg equilibrium. 
The relation of allele frequencies of SNPs to type 2 DM 
in the EWAS was examined with Fisher's exact test. To 
compensate for multiple comparisons of genotypes with 
FPG level or blood HbA1c content or of allele frequencies 
with type 2 DM, we applied Bonferroni’s correction for 
statistical significance of association. Given that 41,265 
SNPs were analyzed, the significance level was set at P 
< 1.21 × 10−6 (0.05/41,265) for the EWASs. Quantile-
quantile plots for P values of genotypes in the EWASs 
for FPG level or blood HbA1c content or for those of 
allele frequencies in the EWAS for type 2 DM are shown 
in Supplementary Figure 4. The inflation factor (λ) was 
1.02 for FPG level, 1.03 for blood HbA1c content, and 
1.26 for type 2 DM. Multivariable logistic regression 
analysis was performed with type 2 DM as a dependent 
variable and independent variables including age, sex (0, 
woman; 1, man), and genotype of each SNP. A detailed 
method of analysis has been described previously [31]. 
The relation of genotypes of identified SNPs to FPG 
level or blood HbA1c content was examined by one-way 
ANOVA. Bonferroni’s correction was also applied to other 
statistical analysis as indicated to compensate for multiple 
comparisons. Statistical tests were performed with JMP 
Genomics version 6.0 software (SAS Institute, Cary, NC, 
USA).
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